Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verastem Inc VSTM

Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced... see more

Recent & Breaking News (NDAQ:VSTM)

Verastem, Inc. (NASDAQ: VSTM) to Ring The NASDAQ Stock Market Closing Bell

GlobeNewswire July 9, 2014

Verastem to Ring the NASDAQ Stock Market Closing Bell and Host Annual Research and Development Day on July 10, 2014

Business Wire July 8, 2014

The Potential of Targeting Cancer Stem Cells Through FAK Inhibition in Mesothelioma Reported in AACR's Cancer Discovery

Business Wire June 24, 2014

Verastem Announces Annual Research and Development Day and Webcast

Business Wire June 18, 2014

Verastem to Present at Upcoming Conferences

Business Wire June 10, 2014

Verastem Presents Updated Clinical Data from VS-6063 and Paclitaxel Combination Phase 1/1b Study in Patients with Ovarian Cancer at the 2014 ASCO Annual Meeting

Business Wire June 2, 2014

Verastem Publishes Scientific Data on Targeting Mesothelioma Cancer Stem Cells in Science Translational Medicine

Business Wire May 27, 2014

Verastem to Present at the 2014 ASCO Annual Meeting

Business Wire May 20, 2014

Verastem to Present at Upcoming Investor Conferences

Business Wire May 14, 2014

Dr. Paul A. Friedman Joins Verastem Board of Directors

Business Wire May 12, 2014

Verastem Announces Initiation of COMMAND Study in Japan

Business Wire May 12, 2014

Verastem Reports First Quarter 2014 Financial and Corporate Results

Business Wire May 8, 2014

Verastem to Present at Upcoming Conferences

Business Wire April 30, 2014

Verastem Presents Data on Cancer Stem Cell-Targeting Agents at the 2014 AACR Annual Meeting

Business Wire April 9, 2014

Verastem to Present Data on Product Candidates Targeting Cancer Stem Cells at the American Association of Cancer Research Meeting

Business Wire March 25, 2014

Verastem to Present at the Boston Business Development Conference

Business Wire March 20, 2014

Timothy J. Barberich Joins Verastem Board of Directors

Business Wire March 11, 2014

Verastem Reports Year-End 2013 Financial Results

Business Wire March 6, 2014

Verastem Reports Data from Phase 1 Study of VS-6063 (defactinib) in Japanese Patients

Business Wire March 5, 2014

Verastem to Present at Upcoming Investor Conferences

Business Wire March 4, 2014